Sale on Ophthalmic Equipment - Starting from 16 November!
Abbott has started the VOYAGER CE trial of its investigational Encantor balloon expandable aortic valve system in up to 300 patients in Europe and Australia.
The Abbott Encantor trial has begun. Abbott said on Thursday that it has started the VOYAGER CE clinical trial of Encantor, its investigational transcatheter aortic valve system. The device uses a balloon to expand the valve and software to guide placement.
The study will assess Encantor in up to 300 patients with symptomatic severe aortic stenosis in Europe and Australia. Macquarie University in Sydney recently enrolled the first patient. VOYAGER CE is a single arm study. It tracks how many patients die or have a stroke within a year of treatment. Abbott intends the findings to support applications for approval in Europe and Australia. It also plans to begin a pivotal US trial in the coming months.
Abbott's design places the replacement valve over a collapsed balloon. A catheter carries both through an artery in the groin. At the diseased valve, software helps the physician fit the expansion to the patient's anatomy. Afterwards the balloon is collapsed and withdrawn, leaving the new valve behind. Dr Didier Tchetche, a co principal investigator, said the design and software approach are meant to give physicians "greater control and procedural confidence".
Doctors treating severe aortic stenosis can choose between balloon expanded and self expanding valves. Edwards Lifesciences uses a balloon expandable frame in its Sapien valves. Medtronic makes self expanding Evolut devices. The Food and Drug Administration approved Abbott's own self expanding Navitor valve in 2023. Abbott sees Encantor as a partner to Navitor, not a replacement. A second Abbott design would let its customers choose between the two approaches for each patient.
The Abbott Encantor trial follows a smaller feasibility study. Abbott reviewed its six month findings before starting VOYAGER CE. It will present data at PCR London Valves 2026, which begins on Sunday.
The Abbott Encantor trial shows the aortic valve market moving towards more choice in how valves expand. Medigear.uk helps clinical buyers compare verified suppliers. Encantor is investigational, so it is not available for routine use in the UK or elsewhere. Trial design and device claims here are Abbott's own.
Source: MedTech Dive
Tell us the model and destination — our sourcing team will respond within one business day.

The Zimmer Monogram robot is now with US regulators. Zimmer Biomet has filed a 510(k) submission for…

Johnson & Johnson (J&J) said on Thursday that a Houston hospital will be the first to instal…

The Exo Gates Foundation grant is worth $11.6 million. Exo, a handheld ultrasound company, announced…
Approvals, trials, recalls and market moves — the essentials for procurement and clinical teams.